

Freedom of Information Request: Our Reference CTMUHB_41_23

You asked:

1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:-

a) Aflibercept	- 1712
b) Bevacizumab	- 19
c) Brolucizumab	- 0
d) Dexamethasone	- 54
e) Faricimab	- 201
f) Ranibizumab – Lucentis	- 10
g) Ranibizumab – Ongavia	- 0

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- a) Aflibercept**
- b) Bevacizumab**
- c) Brolucizumab**
- d) Dexamethasone**
- e) Faricimab**
- f) Ranibizumab - Lucentis**
- g) Ranibizumab - Ongavia**

The level of information requested is not captured on our Medicines Management system. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl through all the Ophthalmology patients treated within this timeframe and would significantly exceed the 18 hours' time and £450 cost limit set out within Section 12 of the Freedom of Information Act.